Ibalizumab

Drug Profile

Ibalizumab

Alternative Names: 5AB; Hu5A8; Monoclonal antibody 5A8; TMB-355; TNX-355

Latest Information Update: 21 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer TaiMed Biologics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; HIV fusion inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 02 Aug 2017 FDA assigns PDUFA action date of 03/01/2018 for ibalizumab for HIV-1 infections (Treatment experienced) (IV)
  • 30 Jun 2017 The US FDA accepts the BLA for ibalizumab for HIV-1 infections for priority review
  • 03 May 2017 Preregistration for HIV-1 infections (Treatment-experienced) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top